University of Cambridge Completes First Human Trial of Sarbecovirus Vaccine
Researchers at the University of Cambridge have successfully completed the first human trial of pEVAC-PS, an AI-designed vaccine aimed at protecting against the entire sarbecovirus family. The trial involved 39 healthy adults aged 18-50 and was published in the Journal of Infection in June 2026. Results indicated that the vaccine was safe and well tolerated, with modest immune responses that support moving to phase 2 trials.
Researchers at the University of Cambridge have completed the first human trial of pEVAC-PS, a vaccine designed by AI to protect against the entire sarbecovirus family, which includes potential future coronaviruses. The study was published in the Journal of Infection in June 2026 and reported on September 24, 2026. A total of 39 healthy adults, aged 18 to 50, took part in the trial, receiving two doses of the vaccine at levels ranging from 0.2 to 1.2 mg.
The results showed that the vaccine was safe and well tolerated across all doses, and the modest immune responses observed support its advancement to phase 2 trials. This marks the first time a vaccine component designed entirely by computer algorithms has undergone human testing, demonstrating the role of AI in public health initiatives.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Aisha travels the world collecting stories of everyday kindness and quiet courage.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
